Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes

Journal of Controlled Release

Volumn 161, Issue 1, 2012, Pages 50-61

  Nieto Montesinos, Rita ^a   Béduneau, Arnaud ^a   Pellequer, Yann ^a   Lamprecht, Alf ^a,b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Drug delivery strategies; Drug efflux; Nanocarriers; P glycoprotein; P gp modulators

Indexed keywords

AMPHIPHILICS; BARRIER FUNCTIONS; BIOLOGICAL ENVIRONMENTS; CHEMICAL TREATMENTS; COLLOIDAL SYSTEM; CONTROLLED RELEASE; DIRECT MODULATION; DRUG EFFLUX; DRUG UPTAKE; NANOCARRIERS; P-GLYCOPROTEIN; RESISTANT CELLS; SUBSTRATE SPECIFICITY; SYNERGISTIC STRATEGY;

DRUG DELIVERY; ENZYME INHIBITION; NANOTECHNOLOGY; SUBSTRATES; SURFACE ACTIVE AGENTS; TISSUE;

GLYCOPROTEINS;

ANTINEOPLASTIC AGENT; CHLORPROMAZINE; COPOLYMER; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; EXCIPIENT; GLYCOPROTEIN P; LANIQUIDAR; LIPOSOME; NANOCARRIER; NANOPARTICLE; NIFEDIPINE; PACLITAXEL; QUINIDINE; QUININE; RESERPINE; SURFACTANT; TAMOXIFEN; TARIQUIDAR; TOPOTECAN; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLLOID; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG POTENTIATION; DRUG UPTAKE; ENCAPSULATION; ENZYME SPECIFICITY; GLIOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; LEUKEMIA; NANOTECHNOLOGY; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; TREATMENT OUTCOME;

ANIMALS; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; P-GLYCOPROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 84862615963     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.04.034     Document Type: Review

References (148)

1. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K.M. Hillgren, K.A. Hoffmaster, T. Ishikawa, D. Keppler, R.B. Kim, C.A. Lee, M. Niemi, J.W. Polli, Y. Sugiyama, P.W. Swaan, J.A. Ware, S.H. Wright, S.W. Yee, M.J. Zamek-Gliszczynski, L. Zhang, Membrane transporters in drug development, Nat. Rev. Drug Discov. 9 (2010) 215-236.
2. W. Loscher, H. Potschka, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases, Prog. Neurobiol. 76 (2005) 22-76. (Pubitemid 41033402)
3. R.L. Juliano, V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochim. Biophys. Acta 455 (1976) 152-162.
4. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, M.M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu. Rev. Pharmacol. Toxicol. 39 (1999) 361-398. (Pubitemid 29222564)
5. R. Krishna, L.D. Mayer, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, Eur. J. Pharm. Sci. 11 (2000) 265-283.
6. N. Akhtar, A. Ahad, R.K. Khar, M. Jaggi, M. Aqil, Z. Iqbal, F.J. Ahmad, S. Talegaonkar, The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review, Expert Opin. Ther. Pat. 21 (2011) 561-576.
7. T. Bansal, N. Akhtar, M. Jaggi, R.K. Khar, S. Talegaonkar, Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation, Drug Discov. Today 14 (2009) 1067-1074.
8. J. Valle, A. Armstrong, C. Newman, V. Alakhov, G. Pietrzynski, J. Brewer, S. Campbell, P. Corrie, E. Rowinsky, M. Ranson, phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction, Invest. New Drugs 29 (2011) 1029-1037.
9. R. Kerb, Implications of genetic polymorphisms in drug transporters for pharmacotherapy, Cancer Lett. 234 (2006) 4-33. (Pubitemid 43343938)
10. W.E. Kaminski, A. Piehler, J.J. Wenzel, ABC A-subfamily transporters: structure, function and disease, Biochim. Biophys. Acta 1762 (2006) 510-524.
11. T.W. Loo, D.M. Clarke, Mutational analysis of ABC proteins, Arch. Biochem. Biophys. 476 (2008) 51-64.
12. I.L. Aye, A.T. Singh, J.A. Keelan, Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function, Chem. Biol. Interact. 180 (2009) 327-339.
13. A.J. Smith, A. van Helvoort, G. van Meer, K. Szabo, E. Welker, G. Szakacs, A. Varadi, B. Sarkadi, P. Borst, MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping, J. Biol. Chem. 275 (2000) 23530-23539. (Pubitemid 30624635)
14. S. Ruetz, P. Gros, Phosphatidylcholine translocase: a physiological role for the mdr2 gene, Cell 77 (1994) 1071-1081. (Pubitemid 24208866)
15. J.J. Smit, A.H. Schinkel, R.P. Oude Elferink, A.K. Groen, E. Wagenaar, L. van Deemter, C.A. Mol, R. Ottenhoff, N.M. van der Lugt, M.A. van Roon, Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease, Cell 75 (1993) 451-462. (Pubitemid 23335071)
16. S.V. Ambudkar, I.W. Kim, Z.E. Sauna, The power of the pump: mechanisms of action of P-glycoprotein (ABCB1), Eur. J. Pharm. Sci. 27 (2006) 392-400. (Pubitemid 43363335)
17. R. Callaghan, R.C. Ford, I.D. Kerr, The translocation mechanism of P-glycoprotein, FEBS Lett. 580 (2006) 1056-1063. (Pubitemid 43185286)
18. M. Hennessy, J.P. Spiers, A primer on the mechanics of P-glycoprotein the multidrug transporter, Pharmacol. Res. 55 (2007) 1-15. (Pubitemid 46108588)
19. M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer 2 (2002) 48-58. (Pubitemid 37328807)
20. E. Yague, A. Arance, L. Kubitza, M. O'Hare, P. Jat, C.M. Ogilvie, I.R. Hart, C.F. Higgins, S. Raguz, Ability to acquire drug resistance arises early during the tumorigenesis process, Cancer Res. 67 (2007) 1130-1137.
21. G.T. Ho, F.M.Moodie, J. Satsangi,Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52 (2003) 759-766. (Pubitemid 36528884)
22. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, M.R. Melamed, J.R. Bertino, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 695-698. (Pubitemid 19037807)
23. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, M.C. Willingham, Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein, J. Histochem. Cytochem. 37 (1989) 159-164. (Pubitemid 19039163)
24. A.H. Schinkel, P-Glycoprotein, a gatekeeper in the blood-brain barrier, Adv. Drug Deliv. Rev. 36 (1999) 179-194. (Pubitemid 29121971)
25. S. Seetharaman, M.A. Barrand, L. Maskell, R.J. Scheper, Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates, J. Neurochem. 70 (1998) 1151-1159. (Pubitemid 28113649)
26. M. Demeule, D. Shedid, E. Beaulieu, R.F. Del Maestro, A. Moghrabi, P.B. Ghosn, R. Moumdjian, F. Berthelet, R. Beliveau, Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors, Int. J. Cancer 93 (2001) 62-66. (Pubitemid 32539502)
27. S. Spiegl-Kreinecker, J. Buchroithner, L. Elbling, E. Steiner, G.Wurm, A. Bodenteich, J. Fischer, M. Micksche, W. Berger, Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes, J. Neurooncol 57 (2002) 27-36. (Pubitemid 34692611)
28. K. Dietzmann, P.V. Bossanyi, D.S. Franke, Expression of P-glycoprotein as a multidrug resistance gene product in human reactive astrocytes and astrocytoma, Zentralbl. Pathol. 140 (1994) 149-153.
29. V.V. Rao, J.L. Dahlheimer, M.E. Bardgett, A.Z. Snyder, R.A. Finch, A.C. Sartorelli, D. Piwnica-Worms, Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3900-3905. (Pubitemid 29169008)
30. G.D. Anderson, D.D. Shen, Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia 48 (2007) 2372-2374. (Pubitemid 350243409)
31. O.L. de Klerk, A.T. Willemsen, M. Roosink, A.L. Bartels, N.H. Hendrikse, F.J. Bosker, J.A. den Boer, Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier, Int. J. Neuropsychopharmacol. 12 (2009) 895-904.
32. M. Uhr, T. Steckler, A. Yassouridis, F. Holsboer, Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption, Neuropsychopharmacology 22 (2000) 380-387. (Pubitemid 30105766)
33. S. Rapposelli, M. Digiacomo, A. Balsamo, P-gp transporter and its role in neurodegenerative diseases, Curr. Top. Med. Chem. 9 (2009) 209-217.
34. M. Strazza, V. Pirrone, B. Wigdahl, M.R. Nonnemacher, Breaking down the barrier: The effects of HIV-1 on the blood-brain barrier, Brain Res. 1399 (2011) 96-115.
35. C.H. Storch, D. Theile, H. Lindenmaier, W.E. Haefeli, J. Weiss, Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein, Biochem. Pharmacol. 73 (2007) 1573-1581. (Pubitemid 46527547)
36. L. Varatharajan, S.A. Thomas, The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research, Antiviral Res. 82 (2009) A99-A109.
37. N.A. Colabufo, F. Berardi, M. Cantore, M. Contino, C. Inglese, M. Niso, R. Perrone, Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials, J. Med. Chem. 53 (2011) 1883-1897.
38. T. Tsuruo, H. Iida, S. Tsukagoshi, Y. Sakurai, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res. 41 (1981) 1967-1972. (Pubitemid 11114605)
39. H. Goldberg, V. Ling, P.Y. Wong, K. Skorecki, Reduced cyclosporin accumulation in multidrug-resistant cells, Biochem. Biophys. Res. Commun. 152 (1988) 552-558.
40. A. Ramu, D. Glaubiger, Z. Fuks, Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues, Cancer Res. 44 (1984) 4392-4395. (Pubitemid 14008754)
41. A.B. Benson III, D.L. Trump, J.M. Koeller, M.I. Egorin, E.A. Olman, R.S. Witte, T.E. Davis, D.C. Tormey, Phase I study of vinblastine and verapamil given by concurrent iv infusion, Cancer Treat. Rep. 69 (1985) 795-799. (Pubitemid 15229417)
42. M.S. Cairo, S. Siegel, N. Anas, L. Sender, Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors, Cancer Res. 49 (1989) 1063-1066. (Pubitemid 19064369)
43. L. Saltz, B. Murphy, N. Kemeny, J. Bertino, W. Tong, D. Keefe, Y. Tzy-Jun, Y. Tao, D. Kelsen, J.P. O'Brien, A phase I trial of intrahepatic verapamil and doxorubicin. Regional therapy to overcome multidrug resistance, Cancer 74 (1994) 2757-2764. (Pubitemid 24340541)
44. J. Verweij, H. Herweijer, R. Oosterom, M.E. van der Burg, A.S. Planting, C. Seynaeve, G. Stoter, K. Nooter, A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance, Br. J. Cancer 64 (1991) 361-364.
45. N.L. Bartlett, B.L. Lum, G.A. Fisher, N.A. Brophy, M.N. Ehsan, J. Halsey, B.I. Sikic, Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance, J. Clin. Oncol. 12 (1994) 835-842. (Pubitemid 24110926)
46. E. Berman, M. McBride, S. Lin, C. Menedez-Botet, W. Tong, Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia, Leukemia 9 (1995) 1631-1637.
47. P.R. Twentyman, N.M. Bleehen, Resistance modification by PSC-833, a novel nonimmunosuppressive cyclosporin [corrected], Eur. J. Cancer 27 (1991) 1639-1642.
48. J.P. Jaffrezou, J.M. Herbert, T. Levade, M.N. Gau, P. Chatelain, G. Laurent, Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein, J. Biol. Chem. 266 (1991) 19858-19864. (Pubitemid 21908305)
49. U.A. Germann, D. Shlyakhter, V.S. Mason, R.E. Zelle, J.P. Duffy, V. Galullo, D.M. Armistead, J.O. Saunders, J. Boger, M.W. Harding, Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro, Anticancer Drugs 8 (1997) 125-140. (Pubitemid 27102228)
50. V. Hollt, M. Kouba, M. Dietel, G. Vogt, Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein, Biochem. Pharmacol. 43 (1992) 2601-2608.
51. V.J. Wacher, C.Y. Wu, L.Z. Benet, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog. 13 (1995) 129-134.
52. V. Fischer, A. Rodriguez-Gascon, F. Heitz, R. Tynes, C. Hauck, D. Cohen, A.E. Vickers, Themultidrug resistancemodulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite, Drug Metab. Dispos. 26 (1998) 802-811. (Pubitemid 28376441)
53. M. Liscovitch, Y. Lavie, Cancer multidrug resistance: a review of recent drug discovery research, IDrugs 5 (2002) 349-355. (Pubitemid 38133051)
54. C. Lhomme, F. Joly, J.L. Walker, A.A. Lissoni, M.O. Nicoletto, G.M. Manikhas, M.M. Baekelandt, A.N. Gordon, P.M. Fracasso, W.L. Mietlowski, G.J. Jones, M.H. Dugan, Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer, J. Clin. Oncol. 26 (2008) 2674-2682.
55. W.R. Friedenberg, M. Rue, E.A. Blood, W.S. Dalton, C. Shustik, R.A. Larson, P. Sonneveld, P.R. Greipp, Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group, Cancer 106 (2006) 830-838. (Pubitemid 43238450)
56. Z. Binkhathlan, D.A. Hamdy, D.R. Brocks, A. Lavasanifar, Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat, Eur. J. Pharm. Biopharm. 75 (2010) 90-95.
57. Y. Shono, H. Nishihara, Y. Matsuda, S. Furukawa, N. Okada, T. Fujita, A. Yamamoto, Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes, J. Pharm. Sci. 93 (2004) 877-885. (Pubitemid 38420399)
58. H. Gelderblom, J. Verweij, K. Nooter, A. Sparreboom, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, Eur. J. Cancer 37 (2001) 1590-1598. (Pubitemid 32778603)
59. R.P. Rago, A. Einstein Jr., R. Lush, T.M. Beer, Y.J. Ko, W.D. Henner, G. Bubley, E.A. Merica, V. Garg, E. Ette, M.W. Harding, W.S. Dalton, Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer, Cancer Chemother. Pharmacol. 51 (2003) 297-305. (Pubitemid 36629807)
60. M.V. Seiden, K.D. Swenerton, U. Matulonis, S. Campos, P. Rose, G. Batist, E. Ette, V. Garg, A. Fuller, M.W. Harding, D. Charpentier, A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy,Gynecol.Oncol. 86 (2002) 302-310. (Pubitemid 35425526)
61. F. Hyafil, C. Vergely, P. Du Vignaud, T. Grand-Perret, In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer Res. 53 (1993) 4595-4602. (Pubitemid 23304385)
62. M. Roe, A. Folkes, P. Ashworth, J. Brumwell, L. Chima, S. Hunjan, I. Pretswell, W. Dangerfield, H. Ryder, P. Charlton, Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives, Bioorg. Med. Chem. Lett. 9 (1999) 595-600. (Pubitemid 29090660)
63. D.L. Slate, N.A. Bruno, S.M. Casey, N. Zutshi, L.J. Garvin, H. Wu, J.R. Pfister, RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance, Anticancer Res. 15 (1995) 811-814.
64. M.J. Newman, J.C. Rodarte, K.D. Benbatoul, S.J. Romano, C. Zhang, S. Krane, E.J. Moran, R.T. Uyeda, R. Dixon, E.S. Guns, L.D. Mayer, Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance, Cancer Res. 60 (2000) 2964-2972. (Pubitemid 30395822)
65. F. Narasaki, M. Oka, M. Fukuda, R. Nakano, K. Ikeda, H. Takatani, K. Terashi, H. Soda, O. Yano, T. Nakamura, L.A. Doyle, T. Tsuruo, S. Kohno, A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene, Cancer Chemother. Pharmacol. 40 (1997) 425-432. (Pubitemid 27346542)
66. D. den Ouden, M. van den Heuvel, M. Schoester, G. van Rens, P. Sonneveld, In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells, Leukemia 10 (1996) 1930-1936. (Pubitemid 27019640)
67. S.P. Letrent, G.M. Pollack, K.R. Brouwer, K.L. Brouwer, Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat, Pharm. Res. 15 (1998) 599-605. (Pubitemid 28214954)
68. M.S. Myer, G. Joone, M.R. Chasen, C.E. van Rensburg, The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoproteinmediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line, Oncol. Rep. 6 (1999) 217-218. (Pubitemid 128532828)
69. A. Sparreboom, A.S. Planting, R.C. Jewell, M.E. van der Burg, A. van der Gaast, P. de Bruijn, W.J. Loos, K. Nooter, L.H. Chandler, E.M. Paul, P.S. Wissel, J. Verweij, Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein, Anticancer Drugs 10 (1999) 719-728. (Pubitemid 30015673)
70. M.M. Malingre, J.H. Beijnen, H. Rosing, F.J. Koopman, R.C. Jewell, E.M. Paul, W.W. Ten Bokkel Huinink, J.H. Schellens, Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients, Br. J. Cancer 84 (2001) 42-47. (Pubitemid 32102502)
71. A.S. Planting, P. Sonneveld, A. van der Gaast, A. Sparreboom, M.E. van der Burg, G.P. Luyten, K. de Leeuw, M. de Boer-Dennert, P.S. Wissel, R.C. Jewell, E.M. Paul, N.B. Purvis Jr., J. Verweij, A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors, Cancer Chemother. Pharmacol. 55 (2005) 91-99. (Pubitemid 40064500)
72. I.E. Kuppens, E.O. Witteveen, R.C. Jewell, S.A. Radema, E.M. Paul, S.G. Mangum, J.H. Beijnen, E.E. Voest, J.H. Schellens, A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients, Clin. Cancer Res. 13 (2007) 3276-3285. (Pubitemid 46944913)
73. C.M. Kruijtzer, J.H. Beijnen, H. Rosing, W.W. ten Bokkel Huinink, M. Schot, R.C. Jewell, E.M. Paul, J.H. Schellens, Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918, J. Clin. Oncol. 20 (2002) 2943-2950. (Pubitemid 34728888)
74. B. Antonsson, F. Conti, A. Ciavatta, S. Montessuit, S. Lewis, I. Martinou, L. Bernasconi, A. Bernard, J.J. Mermod, G. Mazzei, K. Maundrell, F. Gambale, R. Sadoul, J.C. Martinou, Inhibition of Bax channel-forming activity by Bcl-2, Science 277 (1997) 370-372. (Pubitemid 27450709)
75. P. Mistry, A.J. Stewart, W. Dangerfield, S. Okiji, C. Liddle, D. Bootle, J.A. Plumb, D. Templeton, P. Charlton, In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, Cancer Res. 61 (2001) 749-758. (Pubitemid 32128642)
76. J. Abraham, M. Edgerly, R. Wilson, C. Chen, A. Rutt, S. Bakke, R. Robey, A. Dwyer, B. Goldspiel, F. Balis, O. Van Tellingen, S.E. Bates, T. Fojo, A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine, Clin. Cancer Res. 15 (2009) 3574-3582.
77. R.J. Kelly, D. Draper, C.C. Chen, R.W. Robey, W.D. Figg, R.L. Piekarz, X. Chen, E.R. Gardner, F.M. Balis, A.M. Venkatesan, S.M. Steinberg, T. Fojo, S.E. Bates, A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer, Clin. Cancer Res. 17 (2011) 569-580.
78. D. Kurnik, G.G. Sofowora, J.P. Donahue, U.B. Nair, G.R. Wilkinson, A.J. Wood, M. Muszkat, Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein, Anesthesiology 109 (2008) 1092-1099.
79. E.F. Choo, D. Kurnik, M. Muszkat, T. Ohkubo, S.D. Shay, J.N. Higginbotham, H. Glaeser, R.B. Kim, A.J. Wood, G.R. Wilkinson, Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier, J. Pharmacol. Exp. Ther. 317 (2006) 1012-1018. (Pubitemid 43764103)
80. F. Morschhauser, P.L. Zinzani, M. Burgess, L. Sloots, F. Bouafia, C. Dumontet, Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma, Leuk. Lymphoma 48 (2007) 708-715. (Pubitemid 46605542)
81. A. Sandler, M. Gordon, D.P. De Alwis, I. Pouliquen, L. Green, P. Marder, A. Chaudhary, K. Fife, L. Battiato, C. Sweeney, C. Jordan, M. Burgess, C.A. Slapak, A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy, Clin. Cancer Res. 10 (2004) 3265-3272. (Pubitemid 38685430)
82. P.M. Fracasso, L.J. Goldstein, D.P. de Alwis, J.S. Rader, M.A. Arquette, S.A. Goodner, L.P. Wright, C.L. Fears, R.J. Gazak, V.A. Andre, M.F. Burgess, C.A. Slapak, J.H. Schellens, Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies, Clin. Cancer Res. 10 (2004) 7220-7228. (Pubitemid 39487708)
83. J.F. Marcelletti, P.S. Multani, J.E. Lancet, M.R. Baer, B.I. Sikic, Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia, Leuk. Res. 33 (2009) 769-774.
84. J.E. Lancet, M.R. Baer, G.E. Duran, A.F. List, R. Fielding, J.F. Marcelletti, P.S. Multani, B.I. Sikic, A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia, Leuk. Res. 33 (2009) 1055-1061.
85. E.M. Kemper, C. Cleypool, W. Boogerd, J.H. Beijnen, O. van Tellingen, The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice, Cancer Chemother. Pharmacol. 53 (2004) 173-178. (Pubitemid 38186997)
86. B.D. Anderson, M.J. May, S. Jordan, L. Song, M.J. Roberts, M. Leggas, Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective Pglycoprotein inhibitor zosuquidar in rats, DrugMetab. Dispos. 34 (2006) 653-659.
87. L. van Zuylen, A. Sparreboom, A. van der Gaast, K. Nooter, F.A. Eskens, E. Brouwer, C.J. Bol, R. de Vries, P.A. Palmer, J. Verweij, Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933, Eur. J. Cancer 38 (2002) 1090-1099. (Pubitemid 34468014)
88. L. van Zuylen, A. Sparreboom, A. van der Gaast, M.E. van der Burg, V. van Beurden, C.J. Bol, R. Woestenborghs, P.A. Palmer, J. Verweij, The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel, Clin. Cancer Res. 6 (2000) 1365-1371. (Pubitemid 30226221)
89. K.N. Chi, S.K. Chia, R. Dixon, M.J. Newman, V.J. Wacher, B. Sikic, K.A. Gelmon, A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer, Invest. New Drugs 23 (2005) 311-315. (Pubitemid 40980353)
90. C.A. McDevitt, R. Callaghan, How can we best use structural information on Pglycoprotein to design inhibitors? Pharmacol. Ther. 113 (2007) 429-441. (Pubitemid 46149055)
91. E.V. Batrakova, S. Li, Y. Li, V.Y. Alakhov, A.V. Kabanov, Effect of pluronic P85 on ATPase activity of drug efflux transporters, Pharm. Res. 21 (2004) 2226-2233. (Pubitemid 40575635)
92. Z. Zhang, S.S. Feng, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles, Biomaterials 27 (2006) 4025-4033.
93. E. Garcion, A. Lamprecht, B. Heurtault, A. Paillard, A. Aubert-Pouessel, B. Denizot, P. Menei, J.P. Benoit, A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats, Mol. Cancer Ther. 5 (2006) 1710-1722. (Pubitemid 44323239)
94. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, L. Cattel, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, J. Control. Release 100 (2004) 331-346. (Pubitemid 39572916)
95. A.O. Nornoo, D.W. Osborne, D.S. Chow, Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis, Int. J. Pharm. 349 (2008) 108-116. (Pubitemid 350299695)
96. S.M. Moghimi, J. Szebeni, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res. 42 (2003) 463-478. (Pubitemid 37237636)
97. X. Dong, C.A. Mattingly, M.T. Tseng, M.J. Cho, Y. Liu, V.R. Adams, R.J. Mumper, Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP, Cancer Res. 69 (2009) 3918-3926.
98. A.C. de Verdiere, C. Dubernet, F. Nemati, E. Soma, M. Appel, J. Ferte, S. Bernard, F. Puisieux, P. Couvreur, Reversion ofmultidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action, Br. J. Cancer 76 (1997) 198-205. (Pubitemid 27279659)
99. B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, J.P. Benoit, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharm. Res. 19 (2002) 875-880. (Pubitemid 34692585)
100. J.M. Koziara, P.R. Lockman, D.D. Allen, R.J. Mumper, Paclitaxel nanoparticles for the potential treatment of brain tumors, J. Control. Release 99 (2004) 259-269. (Pubitemid 39222111)
101. P. Ma, X. Dong, C.L. Swadley, A. Gupte, M. Leggas, H.C. Ledebur, R.J. Mumper, Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia, J. Biomed. Nanotechnol. 5 (2009) 151-161.
102. D.M. Woodcock, M.E. Linsenmeyer, G. Chojnowski, A.B. Kriegler, V. Nink, L.K. Webster, W.H. Sawyer, Reversal of multidrug resistance by surfactants, Br. J. Cancer 66 (1992) 62-68.
103. Y.L. Lo, Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines, J. Control. Release 90 (2003) 37-48.
104. B.S. De Juan, H. Von Briesen, S.E. Gelperina, J. Kreuter, Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays, J. Drug Target. 14 (2006) 614-622. (Pubitemid 44712357)
105. M.D. Chavanpatil, A. Khdair, B. Gerard, C. Bachmeier, D.W. Miller, M.P. Shekhar, J. Panyam, Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux, Mol. Pharm. 4 (2007) 730-738. (Pubitemid 350004273)
106. V. Munic, Z. Kelneric, L. Mikac, V. Erakovic Haber, Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays, Eur. J. Pharm. Sci. 41 (2010) 86-95.
107. C.Maupas, B.Moulari, A. Beduneau, A. Lamprecht, Y. Pellequer, Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells, Int. J. Pharm. 411 (2011) 136-141.
108. A.V. Kabanov, V.I. Slepnev, L.E. Kuznetsova, E.V. Batrakova, V. Alakhov, N.S. Melik-Nubarov, P.G. Sveshnikov, V.A. Kabanov, Pluronic micelles as a tool for low-molecular compound vector delivery into a cell: effect of Staphylococcus aureus enterotoxin B on cell loading with micelle incorporated fluorescent dye, Biochem. Int. 26 (1992) 1035-1042.
109. J. Zastre, J. Jackson, M. Bajwa, R. Liggins, F. Iqbal, H. Burt, Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block- polycaprolactone diblock copolymers, Eur. J. Pharm. Biopharm. 54 (2002) 299-309. (Pubitemid 35341830)
110. R.D. Dabholkar, R.M. Sawant, D.A. Mongayt, P.V. Devarajan, V.P. Torchilin, Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux, Int. J. Pharm. 315 (2006) 148-157. (Pubitemid 43674120)
111. A.V. Kabanov, E.V. Batrakova, V.Y. Alakhov, Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery, J. Control. Release 82 (2002) 189-212. (Pubitemid 34880178)
112. T. Wang, V.A. Petrenko, V.P. Torchilin, Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity, Mol. Pharm. 7 (2010) 1007-1014.
113. P.K. Dudeja, K.M. Anderson, J.S. Harris, L. Buckingham, J.S. Coon, Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity, Arch. Biochem. Biophys. 319 (1995) 309-315.
114. E.V. Batrakova, S. Li, S.V. Vinogradov, V.Y. Alakhov, D.W. Miller, A.V. Kabanov, Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization, J. Pharmacol. Exp. Ther. 299 (2001) 483-493. (Pubitemid 32979659)
115. S. Zhu, R. Huang, M. Hong, Y. Jiang, Z. Hu, C. Liu, Y. Pei, Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450, Eur. J. Pharm. Sci. 37 (2009) 573-580.
116. B.D. Rege, J.P. Kao, J.E. Polli, Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers, Eur. J. Pharm. Sci. 16 (2002) 237-246.
117. D.Y. Alakhova, N.Y. Rapoport, E.V. Batrakova, A.A. Timoshin, S. Li, D. Nicholls, V.Y. Alakhov, A.V. Kabanov, Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers, J. Control. Release 142 (2011) 89-100.
118. A. Lamprecht, J.P. Benoit, Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition, J. Control. Release 112 (2006) 208-213.
119. E.V. Batrakova, H.Y. Han, D.W. Miller, A.V. Kabanov, Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells, Pharm. Res. 15 (1998) 1525-1532. (Pubitemid 28465737)
120. V. Alakhov, E. Klinski, P. Lemieux, G. Pietrzynski, A. Kabanov, Block copolymeric biotransport carriers as versatile vehicles for drug delivery, Expert Opin. Biol. Ther. 1 (2001) 583-602. (Pubitemid 33769072)
121. D.W. Miller, E.V. Batrakova, T.O.Waltner, V. Alakhov, A.V. Kabanov, Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption, Bioconjug. Chem. 8 (1997) 649-657. (Pubitemid 27416077)
122. X. Zhu, M. Sui, W. Fan, In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel, Anticancer Res. 25 (2005) 1953-1962. (Pubitemid 40904590)
123. J. Zastre, J. Jackson, H. Burt, Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block- Polycaprolactone amphiphilic diblock copolymers, Pharm. Res. 21 (2004) 1489-1497. (Pubitemid 39149666)
124. J. Zastre, J.K. Jackson, W. Wong, H.M. Burt, Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity, J. Pharm. Sci. 96 (2007) 864-875. (Pubitemid 46657874)
125. T. Kobayashi, T. Ishida, Y. Okada, S. Ise, H. Harashima, H. Kiwada, Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells, Int. J. Pharm. 329 (2007) 94-102. (Pubitemid 44937528)
126. D. Goren, A.T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, A. Gabizon, Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump, Clin. Cancer Res. 6 (2000) 1949-1957. (Pubitemid 30305094)
127. X. Wang, J. Li, Y. Wang, L. Koenig, A. Gjyrezi, P. Giannakakou, E.H. Shin, M. Tighiouart, Z.G. Chen, S. Nie, D.M. Shin, A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model, ACS Nano 5 (2011) 6184-6194.
128. J. Wang, B. Goh, W. Lu, Q. Zhang, A. Chang, X.Y. Liu, T.M. Tan, H. Lee, In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells, Biol. Pharm. Bull. 28 (2005) 822-828. (Pubitemid 40740648)
129. Y. Lo, F. Liu, J. Cherng, Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines, J. Control. Release 76 (2001) 1-10. (Pubitemid 32786880)
130. Y.L. Lo, F.I. Liu, J.M. Yang, J.Y. Cherng, Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid, Anticancer Res. 21 (2001) 445-450.
131. R. Krishna, L.D. Mayer, Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors, Cancer Res. 57 (1997) 5246-5253. (Pubitemid 27516357)
132. R. Krishna, N. McIntosh, K.W. Riggs, L.D. Mayer, Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion, Clin. Cancer Res. 5 (1999) 2939-2947. (Pubitemid 29493973)
133. R. Krishna, M. St-Louis, L.D. Mayer, Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin, Int. J. Cancer 85 (2000) 131-141.
134. P.M. Fracasso, K.A. Blum, M.K. Ma, B.R. Tan, L.P. Wright, S.A. Goodner, C.L. Fears, W. Hou, M.A. Arquette, J. Picus, A. Denes, J.E. Mortimer, L. Ratner, S.P. Ivy, H.L. McLeod, Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar, Br. J. Cancer 93 (2005) 46-53. (Pubitemid 41076252)
135. X.R. Song, Z. Cai, Y. Zheng, G. He, F.Y. Cui, D.Q. Gong, S.X. Hou, S.J. Xiong, X.J. Lei, Y.Q. Wei, Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles, Eur. J. Pharm. Sci. 37 (2009) 300-305.
136. J.C. Wang, X.Y. Liu, W.L. Lu, A. Chang, Q. Zhang, B.C. Goh, H.S. Lee, Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats, Eur. J. Pharm. Biopharm. 62 (2006) 44-51. (Pubitemid 41736024)
137. N.R. Patel, A. Rathi, D. Mongayt, V.P. Torchilin, Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes, Int. J. Pharm. 416 (1) (2011) 296-299.
138. J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R.J. Lee, Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil, J. Pharm. Pharm. Sci. 10 (2007) 350-357. (Pubitemid 350065179)
139. J. Du,W.L. Lu, X. Ying, Y. Liu, P. Du,W. Tian, Y. Men, J. Guo, Y. Zhang, R.J. Li, J. Zhou, J.N. Lou, J.C. Wang, X. Zhang, Q. Zhang, Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals, Mol. Pharm. 6 (2009) 905-917.
140. D.H. Levine, P.P. Ghoroghchian, J. Freudenberg, G. Zhang, M.J. Therien, M.I. Greene, D.A. Hammer, R. Murali, Polymersomes: a new multi-functional tool for cancer diagnosis and therapy, Methods 46 (2008) 25-32.
141. C.L. Dai, H.Y. Xiong, L.F. Tang, X. Zhang, Y.J. Liang, M.S. Zeng, L.M. Chen, X.H. Wang, L.W. Fu, Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice, Cancer Chemother. Pharmacol. 60 (2007) 741-750. (Pubitemid 47247285)
142. L. Fu, Y. Liang, L. Deng, Y. Ding, L. Chen, Y. Ye, X. Yang, Q. Pan, Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance, Cancer Chemother. Pharmacol. 53 (2004) 349-356. (Pubitemid 38392360)
143. Z. Pang, L. Feng, R. Hua, J. Chen, H. Gao, S. Pan, X. Jiang, P. Zhang, Lactoferrin-conjugated biodegradable polymersome holding Doxorubicin and tetrandrine for chemotherapy of glioma rats, Mol. Pharm. 7 (2010) 1995-2005.
144. C.E. Soma, C. Dubernet, D. Bentolila, S. Benita, P. Couvreur, Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles, Biomaterials 21 (2000) 1-7.
145. Y. Patil, T. Sadhukha, L. Ma, J. Panyam, Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance, J. Control. Release 136 (2009) 21-29.
146. H.L. Wong, R. Bendayan, A.M. Rauth, X.Y. Wu, Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer, J. Control. Release 116 (2006) 275-284. (Pubitemid 44827405)
147. 4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells, Int. J. Nanomedicine 3 (2008) 277-286.
148. X.R. Song, Y. Zheng, G. He, L. Yang, Y.F. Luo, Z.Y. He, S.Z. Li, J.M. Li, S. Yu, X. Luo, S.X. Hou, Y.Q. Wei, Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma, J. Pharm. Sci. 99 (2010) 4874-4879.